This content is machine translated Annual Meeting of the Swiss Brain Stroke Society, Zurich PCSK9 inhibitors keep acute coronary syndrome at bay It is well known that low LDL cholesterol reduces the risk of cardiovascular disease. But in practice, this is often easier said than done. Are PCSK9 inhibitors the solution?
View Post 7 min This content is machine translated ACC 2018 Success story of PCSK9 inhibition continues For the first time after the highly acclaimed FOURIER trial, a PCSK9 inhibitor now also shows a mortality benefit in secondary prevention. The product in question is alirocumab. Experts are…
